Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  A previously published report provided guidelines for managing the pharmacologic interactions that can result when patientsreceive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called drug-drug because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.
• Subjects:
  AIDS-Related Opportunistic Infections Anti-HIV Agentss Antibiotics, Antitubercular HIV Infections Humans Rifabutin Rifampin Tuberculosis
• Source:
  MMWR. Morbidity and mortality weekly report. 2000; 49(9):185-9.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  11795500
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  5 pdf pages
• Volume:
  49
• Issue:
  9
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
• Main Document Checksum:
  urn:sha-512:3453d4a6b4ce6f606be303e1ddcadbc22f34e0fe395ca6fcb1ea69891680cded7f03328fdd5b6f844b850985b0de94c0a518f3a0e08141728e75308d048c741e
• Download URL:
  https://stacks.cdc.gov/view/cdc/7283/cdc_7283_DS1.pdf
• File Type:
  [PDF - 240.66 KB ]